ERBB2 and breast cancer: IGFIR can phosphorylate and activate the HER2 receptor to negate the effects of anti HER2 therapies in breast cancer cell lines and anti-IGFIR drugs re-sensitize trastuzumab-resistant cell lines to trastuzumab [83,84,85,86].